New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
07:33 EDTBIIB, ABBVBiogen, AbbVie announce results from Phase 3 DECIDE clinical trial
Biogen (BIIB) and AbbVie (ABBV) announced positive top-line results from the Phase 3 DECIDE clinical trial, designed to evaluate the superiority of once-monthly, subcutaneous daclizumab high-yield process when compared to intramuscular interferon beta-1a as a potential treatment for relapsing-remitting multiple sclerosis. Results showed that DAC HYP was superior on the study’s primary endpoint, demonstrating a statistically significant 45% reduction in annualized relapse rate compared to IFN beta-1a. AbbVie Chief Scientific Officer Michael Severino said, "The positive results in the DECIDE study represent achievement of an important milestone in the development of DAC HYP as a potential new treatment option for MS patients. Together, the companies are committed to working with regulatory agencies on filing plans for DAC HYP.” Biogen Idec and AbbVie plan to work with regulatory agencies to determine appropriate timelines for filing.
News For BIIB;ABBV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 20, 2015
07:20 EDTABBVAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
07:18 EDTBIIB, ABBVAmerican Academy of Neurology to hold annual meeting
Subscribe for More Information
April 17, 2015
16:50 EDTABBVAbbVie extends exchange offer to acquire Pharmacyclics
Subscribe for More Information
April 15, 2015
19:08 EDTABBVEnanta confirms AbbVie hepatitis C treatment granted priority review in Japan
Subscribe for More Information
19:03 EDTABBVAbbVie's chronic hepatitis C treatment granted priority review in Japan
Subscribe for More Information
07:14 EDTBIIBBiogen volatility flat into new drug data
Biogen overall option implied volatility of 35 compares to its 26-week average of 34 according to Track Data, suggesting non-directional into results as shares rally in the preopen on Phase 2 RENEW study of anti-LINGO-1 in acute optic neuritis clinical data.
April 14, 2015
18:30 EDTBIIBOn The Fly: After Hours Movers
Subscribe for More Information
16:12 EDTBIIBBiogen presents new Anti-LINGO-1 Phase 2 AON data
Subscribe for More Information
11:25 EDTBIIBPTAB declares interference between Forward Pharma and Biogen regarding treatment
Subscribe for More Information
April 13, 2015
14:07 EDTABBVEarnings Watch: Johnson & Johnson shares down slightly since last earnings
Subscribe for More Information
10:00 EDTABBVOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:34 EDTABBVAbbVie upgraded on Imbruvica outlook at BMO Capital
Subscribe for More Information
07:02 EDTABBVAbbVie upgraded to Outperform from Market Perform at BMO Capital
April 9, 2015
09:25 EDTBIIBPiper Jaffray pharmaceuticals analysts hold an analyst/industry conference call
Subscribe for More Information
07:27 EDTBIIBBiogen PML death case previously reported, says Deutsche Bank
Subscribe for More Information
07:23 EDTBIIBDoctors report case of fatal PML in patient treated with Tecfidera to NEJM
Subscribe for More Information
April 8, 2015
07:24 EDTBIIBNeurotechnology Industry Organization to hold a conference
Subscribe for More Information
05:30 EDTABBVEnanta announces data on regimens containing protease inhibitors paritaprevir
Subscribe for More Information
April 7, 2015
07:31 EDTBIIB, ABBVBiogen to present data on neurological disease therapies at AAN meeting
Subscribe for More Information
07:14 EDTBIIBEyeforpharma to hold a summit
Philadelphia 2015 Commercial Pharma Summit is being held in Philadelphia on April 7-8.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use